how many americans are taking glp-1 Patrick Oben | 1 in 9 now take a medication. That's 11% of U.S. adults — up from just 3% in 2024. Nearly quadrupled in two years. But percentage of americans taking glp

PepsiCo has had an even more muted response and categorized the effect of GLP-1 drugs as negligible

Alternatives in Class At a glance Brand Vyvanse (30-day supply) / $350 to $450 cash price Generic lisdexamfetamine (30-day supply) / $30 to $80 cash price (since August 2023) Generic mixed amphetamine salts XR / $15 to $50 per month Generic methylphenidate ER / $20 to $45 per month FDA-approved indications / ADHD (ages 6+) and binge eating disorder (adults) Duration of action / 12 to 13 hours in controlled trials DEA schedule / Schedule II controlled substance Prodrug conversion / Lisdexamfetamine is cleaved to d-amphetamine in red blood cells Patent expiration / August 2023 (first generics launched) Insurance tier / Tier 2 to 3 for generics

A subset of nondiabetic participants underwent 2 additional study days (approximately 3 months after the first 2) where at 06:00 (180 minutes) an additional infusion of Intralipid (20%, 0.011 mL/kg/minute

For an athlete relying on rapid carbohydrate delivery during a marathon, this means gels and sports drinks sit in the stomach longer before they become available as fuel

Other pharmaceutical companies began developing their own GLP-1 drugs to improve upon Byetta